PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Earnings improvement at core subsidiary Infinitt Healthcare and a governance dispute with minority shareholders are unfolding in parallel.
Solbon is a de facto holding company classified as an investment company that does not file a separate business report; consolidated results hinge on Infinitt Healthcare and Solbon Investment.
2025 consolidated revenue rose 3.9% and operating profit rose 16.4% year over year, while owners' net profit fell 38.5%.
First-quarter 2026 consolidated revenue grew 42.2% year over year, with both operating profit and net profit turning positive.
Infinitt Healthcare's board terminated its management-consulting contract with Solbon in December 2025 and decided to reclaim the fees paid that year.
The INFINITT DPS digital pathology solution received US FDA clearance in December 2025, widening its US market entry channel.
Solbon, founded in 1994, is a holding company whose stated business purposes are equity participation in other companies and real estate leasing, and it is classified as an investment company that does not file a separate business report.
As of 2025 it held 14 affiliates and effectively operates as a holding company spanning medical IT and venture investment.
Its core subsidiary is KOSDAQ-listed Infinitt Healthcare (071200), which focuses on manufacturing and selling Picture Archiving and Communication Systems (PACS); minority shareholders have stated the company holds roughly a 75% share of the PACS market at tertiary general hospitals and about 70% at general hospitals domestically.
Another pillar is venture capital affiliate Solbon Investment, which generates returns through investments in small and midsize venture firms and overseas-listed equities. The group also includes media affiliate Focus Newspaper and a number of venture investment vehicles.
Infinitt Healthcare had for years paid annual fees to parent Solbon under management-consulting and asset-management arrangements, but its board decided in December 2025 to terminate that service contract and reclaim the fees paid during the year.
The company describes its strategy as leveraging the holding-company structure to improve affiliate management efficiency and transparency while pursuing new businesses to maximize corporate value.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩40.2B | ₩21.8B | 54.2% |
| 2025Q3 | ₩27B | ₩4.4B | 16.5% |
| 2025Q4 | ₩28.7B | ₩4.4B | 15.2% |
| 2026Q1 | ₩35.3B | ₩3.6B | 10.3% |
| 2026Q2 | ₩35B | ₩16B | 45.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩93.8B | -₩26.8B | -₩41.7B | −28.6% | −33.7% | 21.0% |
| 2023 | ₩123.4B | ₩31.8B | ₩38.2B | 25.7% | 23.2% | 19.4% |
| 2024 | ₩116.1B | ₩21.2B | ₩34B | 18.2% | 16.8% | 19.5% |
| 2025 | ₩120.7B | ₩24.6B | ₩20.9B | 20.4% | 9.8% | 20.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue moved from about KRW 93.8 billion in 2022 to KRW 123.4 billion in 2023, KRW 116.1 billion in 2024, and KRW 120.7 billion in 2025, settling in the low-KRW-120-billion range.
Operating profit swung from a large loss of roughly KRW -26.8 billion in 2022 to a profit of about KRW 31.8 billion in 2023, followed by KRW 21.2 billion in 2024 and KRW 24.6 billion in 2025, with the operating margin fluctuating from -28.6% in 2022 to 25.7% in 2023, 18.2% in 2024, and 20.4% in 2025.
Owners' net profit reversed from about KRW -41.7 billion in 2022 to roughly KRW 38.2 billion in 2023, but then declined for two straight years to about KRW 34.0 billion in 2024 and KRW 20.9 billion in 2025, diverging from the revenue and operating-profit growth trend.
In fact, the 2025 results showed revenue up 3.9% and operating profit up 16.4% year over year, while net profit fell 38.5%, a pattern interpreted as reflecting large swings in non-operating items layered on top of operating improvement at the core subsidiary.
Quarterly figures show pronounced volatility: second-quarter 2025 owners' net profit was about KRW 20.1 billion against revenue of KRW 40.2 billion, an unusually large gap, before falling to KRW 14.8 billion in the third quarter and turning to a loss of about KRW -5.3 billion in the fourth quarter.
First-quarter 2026 owners' net profit stayed modestly positive at about KRW 1.4 billion, then expanded sharply again in the second quarter to revenue of KRW 35.0 billion, operating profit of KRW 16.0 billion, and owners' net profit of KRW 24.3 billion, reconfirming the large quarter-to-quarter swings.
Separate industry data indicate first-quarter 2026 consolidated revenue rose 42.2% year over year with both operating profit and net profit turning positive, a result attributed to growth in the medical device business at core subsidiary Infinitt Healthcare.
These large swings in quarterly earnings appear to stem from the holding-company structure, in which equity-method gains and losses from affiliates and valuation gains and losses on investment assets are also reflected in results.
Solbon is classified under the real estate and REIT sector on KOSDAQ, but its actual profit and loss are driven by a holding-company structure whose results depend on a medical IT subsidiary and an investment portfolio.
The medical imaging IT market served by core subsidiary Infinitt Healthcare continues to grow moderately, supported by hospitals' digital transformation and rising demand for clinical data management amid an aging population.
In digital pathology, INFINITT DPS received US FDA 510(k) clearance in December 2025 for primary diagnosis use on tissue slides, widening its channel into the US market.
Infinitt North America stated in December 2025 that it expanded its pathology platform by integrating FDA-cleared Hamamatsu scanners with the INFINITT DPS solution.
That said, minority shareholders have argued the domestic PACS market is closer to a mature market with already-high shares concentrated at tertiary general hospitals.
Results at venture-investment affiliate Solbon Investment are linked to domestic venture-investment sentiment and overseas listed-equity market conditions, so capital-market volatility feeds directly into the holding company's consolidated results.
On the competitive front, minority shareholders have argued that while numerous players operate in the domestic medical IT market, Infinitt Healthcare holds a relatively leading position in the tertiary-hospital PACS segment.
With the December 2025 US FDA 510(k) clearance for INFINITT DPS, a push into the US digital pathology market is expected to gain momentum, and Infinitt North America is expanding its product portfolio through integrations such as the Hamamatsu scanner.
The 42.2% revenue growth and simultaneous swing to operating and net profit confirmed in first-quarter 2026 results show that the core subsidiary's medical device business continues to expand.
On the governance front, Infinitt Healthcare's board decided on December 17, 2025 to terminate its management-consulting service contract with Solbon and reclaim roughly KRW 2.6 billion in fees paid during 2025.
This means one non-operating fee revenue stream that Solbon had received from its subsidiary will disappear going forward.
At the same board meeting, Infinitt Healthcare said it would continue reviewing expanded shareholder-return measures, including further dividends beyond its quarterly payout, which matters for Infinitt Healthcare's own shareholder value but could signal a change in the flow of funds to Solbon.
Minority-shareholder activist platform Heyholder has said its push for governance reform remains unchanged and that it is considering further action, including an appeal of the court's ruling, indicating the dispute has not fully concluded.
The company has stated it intends to resolve unnecessary sources of management-control disputes going forward and focus on strengthening business competitiveness and enhancing shareholder value.
Because of Solbon's holding-company structure, consolidated results incorporate substantial equity-method gains and losses from affiliates and valuation gains and losses on investment assets, and given the large quarter-to-quarter swings in profit, a single-point earnings multiple does not fully capture the underlying earning power of the business.
Owners' equity has grown steadily, from about KRW 123.8 billion in 2022 to about KRW 212.6 billion in 2025, showing capital accumulation since the company moved past its loss year.
The shares tend to trade at a discount to net asset value, which some interpret as consistent with the discount-to-net-asset-value pattern common among holding companies.
No separate dividend has been paid recently, so the attractiveness of shareholder returns may hinge on whether subsidiary Infinitt Healthcare expands its own dividend going forward.
Looking at the most recent four quarters together, earnings volatility has continued, with a loss in the fourth quarter of 2025 crossing paths with a large profit in the second quarter of 2026, a pattern worth bearing in mind when interpreting the figures.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Core subsidiary Infinitt Healthcare's medical device business is showing growth, evidenced by first-quarter 2026 revenue growth of 42.2% and a simultaneous swing to operating and net profit. The US FDA clearance for INFINITT DPS has laid a foundation for expanding overseas revenue.
Consolidated revenue also grew from about KRW 116.1 billion in 2024 to KRW 120.7 billion in 2025, reflecting an expanding overall top line for the holding company.
After a large loss in 2022 (operating profit of about KRW -26.8 billion and owners' net loss of about KRW -41.7 billion), the company posted three consecutive years of operating profit from 2023 to 2025, and owners' equity grew from about KRW 123.8 billion in 2022 to KRW 212.6 billion in 2025.
The operating margin also improved from -28.6% in 2022 to 20.4% in 2025, indicating a recovery in the profit structure.
The Infinitt Healthcare board's decision to terminate its management-consulting contract with Solbon and reclaim the associated fees is interpreted as a step toward resolving controversy over related-party transactions.
The company has stated it intends to reduce sources of management-control disputes and focus on enhancing shareholder value. This could contribute to improved governance transparency across the group over the longer term.
Owners' net profit declined for two consecutive years, from about KRW 38.2 billion in 2023 to KRW 34.0 billion in 2024 and KRW 20.9 billion in 2025, and quarterly results have alternated sharply, from a loss of about KRW -5.3 billion in the fourth quarter of 2025 to a profit of about KRW 24.3 billion in the second quarter of 2026, making the profit pattern difficult to forecast. Periods in which revenue and operating profit growth diverge from the net profit trend have recurred.
The arrangement under which Infinitt Healthcare paid Solbon tens of billions of won annually for management-consulting and asset-management services was ended by the December 2025 contract termination.
This means one of Solbon's non-operating revenue streams will disappear going forward, and its impact on consolidated results warrants monitoring.
Activist platform Heyholder and other minority shareholders have said they will continue pushing for governance reform and are considering further legal action, including an appeal of the court's ruling.
Infinitt Healthcare entered a listing-eligibility review process following a disclosure of alleged breach of trust by a former CEO, so related uncertainty has not been fully resolved.
A management-control dispute with minority shareholders over Infinitt Healthcare has continued, with repeated legal actions including petitions for court-ordered shareholder meetings and injunctions.
A listing-eligibility review process was triggered by a disclosure of alleged breach of trust by a former CEO, and uncertainty tied to the outcome of that review remains.
Solbon Investment generates returns through investments in small and midsize venture companies and overseas-listed equities, so valuation gains and losses can swing significantly with capital-market conditions.
The large swings in quarterly net profit are presumed to be linked to fluctuations in these investment-asset gains and losses.
A substantial portion of consolidated results depends on the performance of a single subsidiary, Infinitt Healthcare, so weaker competitive positioning in the medical IT market or a slow US market rollout would have an outsized effect on group results.
This is compounded by the loss of fee income from reduced related-party transactions, leaving revenue diversification as an ongoing challenge.
Third-quarter 2026 consolidated results are expected to be disclosed — a point to check whether Infinitt Healthcare's revenue growth continues and whether quarterly net profit volatility eases.
Check for new US sales contracts and revenue contribution from INFINITT DPS — a way to gauge tangible progress in the US digital pathology market.
Monitor whether minority shareholders such as Heyholder pursue further legal action (e.g., an appeal) and follow-up steps in Infinitt Healthcare's listing-eligibility review.
Check whether Infinitt Healthcare finalizes expanded shareholder-return measures such as higher dividends, and whether Solbon identifies alternative funding sources to offset the revenue lost from the terminated management-consulting fee arrangement.
Solbon is a holding company classified as an investment company that does not file a separate business report, with consolidated results depending heavily on the medical IT business of listed subsidiary Infinitt Healthcare and the investment performance of Solbon Investment.
Having moved past a large loss in 2022, the company sustained operating profit from 2023 through 2025, though owners' net profit declined for two consecutive years in 2024 and 2025 and quarterly results have shown large swings.
Since the first quarter of 2026, Infinitt Healthcare's revenue expansion and swing to profit have been confirmed, and the US FDA clearance for INFINITT DPS has laid a foundation for overseas market entry.
At the same time, governance and legal risks persist, including the dispute with minority shareholders over Infinitt Healthcare, the change in Solbon's revenue sources following termination of the management-consulting fee contract, and the history of a listing-eligibility review.
Investors will want to weigh the subsidiary's earnings-improvement trend alongside these governance-related uncertainties.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.